Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Saved in:
| Title: | Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. |
|---|---|
| Authors: | Kircik LH; Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Indiana Medical Center, Indianapolis, IN, USA.; Physicians Skin Care PLLC, Louisville, KY, USA.; Skin Sciences PLLC, Louisville, KY, USA., Alonso-Llamazares J; Driven Research LLC, Coral Gables, FL, USA., Bhatia N; Therapeutics Clinical Research, San Diego, CA, USA., Bukhalo M; Arlington Dermatology, Rolling Meadows, IL, USA., Devani AR; Dermatology Research Institute, Calgary, AB, Canada.; Skin Health and Wellness Centre, Calgary, AB, Canada.; Probity Medical Research, Calgary, AB, Canada., Draelos ZD; Dermatology Consulting Services, High Point, NC, USA., DuBois J; DermResearch Inc., Austin, TX, USA., Gooderham MJ; SkiN Centre for Dermatology, Peterborough, ON, Canada.; Probity Medical Research, Peterborough, ON, Canada.; Queen's University, Peterborough, ON, Canada., Kempers SE; Minnesota Clinical Study Center, Fridley, MN, USA., Lain E; Sanova Dermatology, Austin, TX, USA., Lee M; Progressive Clinical Research, San Antonio, TX, USA., Moore A; Arlington Research Center, Arlington, TX, USA.; Baylor University Medical Center, Dallas, TX, USA., Murrell DF; Faculty of Medicine, University of NSW, Sydney, Australia., Papp KA; Probity Medical Research, Waterloo, ON, Canada.; K. Papp Clinical Research, Waterloo, ON, Canada., Pariser DM; Eastern Virginia Medical School, Norfolk, VA, USA.; Virginia Clinical Research Inc., Norfolk, VA, USA., Sinclair R; Sinclair Dermatology, East Melbourne, Australia., Zirwas M; Dermatologists of the Central States, Probity Medical Research, Bexley, OH, USA.; Ohio University, Bexley, OH, USA., Burnett P; Arcutis Biotherapeutics Inc., Westlake Village, CA, USA., Higham RC; Arcutis Biotherapeutics Inc., Westlake Village, CA, USA., Krupa D; Arcutis Biotherapeutics Inc., Westlake Village, CA, USA., Berk DR; Arcutis Biotherapeutics Inc., Westlake Village, CA, USA. |
| Source: | The British journal of dermatology [Br J Dermatol] 2023 Sep 15; Vol. 189 (4), pp. 392-399. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2133 |
|---|---|
| DOI: | 10.1093/bjd/ljad182 |
